BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Sola P, Krishnamurthy P, Chintamaneni PK, Pindiprolu SKS, Kumari M. Novel drug delivery systems of β2 adrenoreceptor agonists to suppress SNCA gene expression and mitochondrial oxidative stress in Parkinson’s disease management. Expert Opinion on Drug Delivery 2020;17:1119-32. [DOI: 10.1080/17425247.2020.1779218] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
Number Citing Articles
1 Ahmad J, Haider N, Khan MA, Md S, Alhakamy NA, Ghoneim MM, Alshehri S, Sarim Imam S, Ahmad MZ, Mishra A. Novel therapeutic interventions for combating Parkinson's disease and prospects of Nose-to-Brain drug delivery. Biochem Pharmacol 2022;195:114849. [PMID: 34808125 DOI: 10.1016/j.bcp.2021.114849] [Reference Citation Analysis]
2 Krishnan UM. Biomaterials in the treatment of Parkinson's disease. Neurochem Int 2021;145:105003. [PMID: 33657427 DOI: 10.1016/j.neuint.2021.105003] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]